243 related articles for article (PubMed ID: 21695163)
1. Vorinostat induces reactive oxygen species and DNA damage in acute myeloid leukemia cells.
Petruccelli LA; Dupéré-Richer D; Pettersson F; Retrouvey H; Skoulikas S; Miller WH
PLoS One; 2011; 6(6):e20987. PubMed ID: 21695163
[TBL] [Abstract][Full Text] [Related]
2. Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway.
Yaseen A; Chen S; Hock S; Rosato R; Dent P; Dai Y; Grant S
Mol Pharmacol; 2012 Dec; 82(6):1030-41. PubMed ID: 22923501
[TBL] [Abstract][Full Text] [Related]
3. Expression of leukemia-associated fusion proteins increases sensitivity to histone deacetylase inhibitor-induced DNA damage and apoptosis.
Petruccelli LA; Pettersson F; Del Rincón SV; Guilbert C; Licht JD; Miller WH
Mol Cancer Ther; 2013 Aug; 12(8):1591-604. PubMed ID: 23536727
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.
Lee JH; Choy ML; Ngo L; Foster SS; Marks PA
Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14639-44. PubMed ID: 20679231
[TBL] [Abstract][Full Text] [Related]
5. Antioxidants impair anti-tumoral effects of Vorinostat, but not anti-neoplastic effects of Vorinostat and caspase-8 downregulation.
Bergadà L; Yeramian A; Sorolla A; Matias-Guiu X; Dolcet X
PLoS One; 2014; 9(3):e92764. PubMed ID: 24651472
[TBL] [Abstract][Full Text] [Related]
6. A novel alkylating deacetylase inhibitor molecule EDO-S101 in combination with cytarabine synergistically enhances apoptosis of acute myeloid leukemia cells.
Jin J; Mao S; Li F; Li X; Huang X; Yu M; Guo W; Jin J
Med Oncol; 2019 Aug; 36(9):77. PubMed ID: 31372848
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.
Bruzzese F; Rocco M; Castelli S; Di Gennaro E; Desideri A; Budillon A
Mol Cancer Ther; 2009 Nov; 8(11):3075-87. PubMed ID: 19887547
[TBL] [Abstract][Full Text] [Related]
8. Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways.
Sampson VB; Vetter NS; Kamara DF; Collier AB; Gresh RC; Kolb EA
PLoS One; 2015; 10(11):e0142704. PubMed ID: 26571493
[TBL] [Abstract][Full Text] [Related]
9. Vorinostat induces apoptosis and differentiation in myeloid malignancies: genetic and molecular mechanisms.
Silva G; Cardoso BA; Belo H; Almeida AM
PLoS One; 2013; 8(1):e53766. PubMed ID: 23320102
[TBL] [Abstract][Full Text] [Related]
10. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
[TBL] [Abstract][Full Text] [Related]
11. Generation of reactive oxygen species during apoptosis induced by DNA-damaging agents and/or histone deacetylase inhibitors.
Brodská B; Holoubek A
Oxid Med Cell Longev; 2011; 2011():253529. PubMed ID: 21949898
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage.
Premkumar DR; Jane EP; Agostino NR; DiDomenico JD; Pollack IF
Mol Carcinog; 2013 Feb; 52(2):118-33. PubMed ID: 22086447
[TBL] [Abstract][Full Text] [Related]
13. Epigenetics targeted protein-vorinostat nanomedicine inducing apoptosis in heterogeneous population of primary acute myeloid leukemia cells including refractory and relapsed cases.
Chandran P; Kavalakatt A; Malarvizhi GL; Vasanthakumari DR; Retnakumari AP; Sidharthan N; Pavithran K; Nair S; Koyakutty M
Nanomedicine; 2014 May; 10(4):721-32. PubMed ID: 24103301
[TBL] [Abstract][Full Text] [Related]
14. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate.
Hu Y; Lu W; Chen G; Zhang H; Jia Y; Wei Y; Yang H; Zhang W; Fiskus W; Bhalla K; Keating M; Huang P; Garcia-Manero G
Blood; 2010 Oct; 116(15):2732-41. PubMed ID: 20566897
[TBL] [Abstract][Full Text] [Related]
15. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.
Fiskus W; Rao R; Fernandez P; Herger B; Yang Y; Chen J; Kolhe R; Mandawat A; Wang Y; Joshi R; Eaton K; Lee P; Atadja P; Peiper S; Bhalla K
Blood; 2008 Oct; 112(7):2896-905. PubMed ID: 18660379
[TBL] [Abstract][Full Text] [Related]
16. HDAC inhibitor Vorinostat and BET inhibitor Plx51107 epigenetic agents' combined treatments exert a therapeutic approach upon acute myeloid leukemia cell model.
Alcitepe İ; Salcin H; Karatekin İ; Kaymaz BT
Med Oncol; 2022 Oct; 39(12):257. PubMed ID: 36224430
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
Rivera-Del Valle N; Cheng T; Irwin ME; Donnella H; Singh MM; Chandra J
Cancer Chemother Pharmacol; 2018 Mar; 81(3):483-495. PubMed ID: 29313067
[TBL] [Abstract][Full Text] [Related]
18. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial effects of PARP inhibitor PJ34 and histone deacetylase inhibitor vorinostat on leukemia cell lines.
Jasek E; Gajda M; Lis GJ; Jasińska M; Litwin JA
Anticancer Res; 2014 Apr; 34(4):1849-56. PubMed ID: 24692719
[TBL] [Abstract][Full Text] [Related]
20. Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells.
Mühlethaler-Mottet A; Meier R; Flahaut M; Bourloud KB; Nardou K; Joseph JM; Gross N
Mol Cancer; 2008 Jun; 7():55. PubMed ID: 18549473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]